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Abstract  
An array of self-reported, clinician-rated, and performance-based measures has been used to 
assess motivation in schizophrenia; however, the convergent validity evidence for these 
motivation assessment methods is mixed. The current study is a series of meta-analyses that 
summarized the relationship between methods of motivation measurement in 45 studies of 
people with schizophrenia. The overall mean effect size between self-reported and clinician-rated 
motivation measures (r = .27, k = 33) was significant, positive, and approaching medium in 
magnitude, and the overall effect size between performance-based and clinician-rated motivation 
measures (r = .21, k = 11) was positive, significant, and small in magnitude. The overall mean 
effect size between self-reported and performance-based motivation measures was negligible and 
non-significant (r = -.001, k = 2), but this meta-analysis was underpowered. Findings suggest 
modest convergent validity between clinician-rated and both self-reported and performance-
based motivation measures, but additional work is needed to clarify the convergent validity 
between self-reported and performance-based measures. Further, there is likely more variability 
than similarity in the underlying construct that is being assessed across the three methods, 
particularly between the performance-based and other motivation measurement types. These 
motivation assessment methods should not be used interchangeably, and measures should be 
more precisely described as the specific motivational construct or domain they are capturing.  
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Among people with schizophrenia, motivation deficits have long been observed (Bleuler, 
1911/1950; Kraepelin, 1913/1919) and are among the strongest determinants of reduced 
functioning and quality of life (Fervaha, Foussias, Agid, & Remington, 2014; Foussias et al., 
2011; Kirkpatrick, Fenton, Carpenter, & Marder, 2006). The functional significance of 
motivation, coupled with the consensus statement on negative symptoms from the National 
Institute of Mental Health and Treatment Research to Improve Cognition in Schizophrenia 
(Kirkpatrick, Fenton, Carpenter, & Marder, 2006), has contributed to a burgeoning area of 
research focused on the assessment of motivation in schizophrenia. To date, a panoply of 
measures has been used to assess motivation in schizophrenia, including self-reported, clinician-
rated, and performance-based measures. However, the degree to which these measures assess a 
similar underlying construct is not clear (J. Choi, Choi, Reddy, & Fiszdon, 2014; Fervaha, 
Foussias, Takeuchi, Agid, & Remington, 2015; Kremen, Fiszdon, Kurtz, Silverstein, & Choi, 
2016). Determining the overlap or discrepancy between the underlying construct of these 
measures is needed to clarify the nature of motivation deficits in schizophrenia and develop 
effective treatments for these deficits. If measures are indeed assessing disparate constructs or 
constructs that are not directly related to motivation, then using them to evaluate treatments may 
provide little insight into the effectiveness of an intervention. Thus, these meta-analyses examine 
the degree of convergence between self-reported, clinician-rated, and performance-based 
measures of motivation used in existing studies involving people with schizophrenia-spectrum 
disorders.  
Conceptualization of Motivation in Schizophrenia Research  
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 Although numerous definitions of motivation have been proposed, motivation is 
generally defined as an internal state that initiates, directs, and maintains goal-directed behavior 
(Kleinginna & Kleinginna, 1981). Within schizophrenia research, motivation deficits are often 
described as falling under the umbrella of negative symptoms but have been found to be partially 
independent of negative symptoms (Luther, Lysaker, Firmin, Breier, & Vohs, 2015; Saperstein, 
Fiszdon, & Bell, 2011; Yamada, Lee, Dinh, Barrio, & Brekke, 2010). Recently, researchers have 
begun to differentiate motivation domains in schizophrenia, with many (c.f., J. Choi, Mogami, & 
Medalia, 2010; Gard et al., 2014; Medalia & Brekke, 2010) looking to Self-Determination 
Theory (SDT; Deci & Ryan, 1985a, Ryan and Deci, 2000a) to conceptualize the specific 
domains of motivation in schizophrenia. SDT posits that there are three types of motivation 
differentiated by the underlying reason for a behavior: intrinsic motivation, extrinsic motivation, 
and amotivation. Given the prominence of SDT and these motivation domains in schizophrenia 
research, each of these domains will be briefly reviewed.    
Intrinsic motivation, which is often defined as pursuing a task or action because it is 
enjoyable or interesting (Ryan & Deci, 2000a), has recently received considerable attention in 
schizophrenia research in part because of its associations with cognitive performance (Fervaha, 
Zakzanis, et al., 2014) and functioning (Luther, Firmin, Vohs, et al., 2016). Importantly, 
clinician-rated intrinsic motivation has been found to be overlapping but distinct from clinician-
rated amotivation and overall negative symptoms (Luther et al., 2015; Yamada et al., 2010). 
However, somewhat surprisingly, self-reported intrinsic motivation measures frequently 
demonstrate small correlations with clinican-rated intrinsic motivation or negative symptom 
measures (Barch, Yodkovik, Sypher-Locke, & Hanewinkel, 2008; Breitborde, Woolverton, 
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Frost, & Kiewel, 2014; J. Choi et al., 2014), leading to calls for additional evaluation of the 
overlap between extant motivation measures (J. Choi et al., 2014; Cooper et al., 2015). 
Extrinsic motivation, or pursuing a task or action in order to obtain an outcome different 
from the task itself, such as an external reward (i.e., monetary reward or praise) or to avoid 
punishment (Ryan & Deci, 2000a), has long been an area of interest in psychotherapeutic 
treatment in schizophrenia. Indeed, the use of rewards has been a main component used to 
facilitate skill attainment, treatment engagement, learning, and improved behavior in token 
economies (Werry, 1969) and social learning programs (Glynn & Mueser, 1986) for people with 
schizophrenia. More recently, a burgeoning area of research has found that people with 
schizophrenia demonstrate impaired external reward processing in the areas of value 
representations—identifying and updating mental representations of reward value associated 
with a task (Gold, Waltz, Prentice, Morris, & Heerey, 2008; Strauss, Waltz, & Gold, 2014)—and 
effort-cost computations or estimating whether the benefits outweigh the effort or costs 
associated with completing a task (Gold et al., 2013; Green, Horan, Barch, & Gold, 2015). These 
findings have led researchers to posit that these reward processing deficits are key processes 
underlying motivation deficits in schizophrenia (Gold et al., 2008; Strauss et al., 2014). 
However, studies examining the association between performance on reward processing tasks 
(e.g., effort-based decision-making tasks) and clinician-rated amotivation or negative symptoms 
have revealed mixed findings (c.f., McCarthy et al., 2016; Treadway et al., 2015). One reason for 
these incongruent findings is that many studies consisted of small samples (e.g., 16 people; 
Fervaha, Graff-Guerrero, et al., 2013), limiting their power to detect significant associations. By 
examining associations across multiple studies, a comprehensive meta-analytic approach can 
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offset small sample sizes and may offer additional clarity regarding the association between 
these measures. 
Finally, amotivation, or lacking the impetus or intention to carry out a task or action 
(Ryan & Deci, 2000a), has long been an area of interest in schizophrenia (Bleuler, 1911/1950; 
Kraepelin, 1913/1919). Amotivation has been conceptualized as one of two key subdomains of 
negative symptoms (American Psychiatric Association, 2013; Marder & Galderisi, 2017) and is 
related to, but distinct from, the second negative symptom domain of diminished expression 
symptoms (i.e., blunted affect, alogia). Moreover, these negative symptom domains have 
demonstrated differential associations with other clinical variables, with some research showing 
that amotivation is more strongly linked to both functioning and neurocognition than diminished 
expression negative symptoms (Green, Hellemann, Horan, Lee, & Wynn, 2012; Strauss et al., 
2013).  
Measuring Motivation in Schizophrenia   
Self-reported motivation measures. Numerous self-reported measures have been used 
to assess these three motivation domains. One of the most recent and widely used self-reported 
motivation measures is the Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR; 
J. Choi et al., 2010), which is derived from SDT and includes subscales of interest/enjoyment, 
effort, and competence. The IMI-SR was developed to measure state intrinsic motivation for a 
particular task—most frequently the IMI-SR is used to measure intrinsic motivation for cognitive 
remediation or computerized learning tasks but has also been used by Cooper et al. (2015) to 
measure participants’ intrinsic motivation for “an important task they recently completed” 
(Cooper et al., 2015, p. 72). The IMI-SR has gained notable traction, in part because it was one 
of the first non-negative symptom (i.e., amotivation) measures of motivation to be validated in a 
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schizophrenia sample. Further, although some have expressed concerns about obtaining reliable 
data on self-reported measures from people with schizophrenia (Gupta, Holshausen, Gou, & 
Bowie, 2014; Takeuchi, Fervaha, & Remington, 2016), others have posited that because intrinsic 
motivation reflects internal states (i.e., the enjoyment one derives from an activity or the reason 
behind completing an activity), intrinsic motivation can only be truly measured with a self-
reported measure (J. Choi et al., 2014; Kremen et al., 2016).  
More recently, Cooper and colleagues (2015) modified and validated a clinical version of 
the General Causality Orientation Scale (GCOS; Deci & Ryan, 1985b) for use with people with 
schizophrenia and other severe mental illnesses (GCOS-clinical populations: GCOS-CP). The 
GCOS is another SDT-derived measure that uses vignettes to assess three trait-like motivation 
orientations—relatively enduring aspects of personality that underlie how a person generally 
initiates and regulates behavior (Deci & Ryan, 1985b). After reading each vignette, participants 
are asked to imagine themselves in that situation and rate several items based on how they would 
likely respond. The three GCOS motivation orientations assessed are autonomy, control, and 
impersonal, which map onto the domains of intrinsic motivation, extrinsic motivation, and 
amotivation, respectively. However, studies examining the association between the GCOS, 
GCOS-CP, and IMI-SR and clinician-rated negative symptoms have demonstrated mixed 
findings, with some finding small correlations and others finding medium correlations (c.f., J. 
Choi et al., 2014; J. Choi, Fiszdon, & Medalia, 2010; Cooper et al., 2015). Importantly, however, 
most prior studies examined the association between these scales and a broader range of negative 
symptoms (i.e., total scores); thus, examining the association between these scales and the 
amotivation negative symptom domain can provide a more precise test of the convergent validity 
of these scales.  
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Other self-reported measures of motivation include negative symptom self-reported 
scales that assess amotivation. Lincoln, Dollfus, and Lyne (2017) recently conducted a 
comprehensive review of negative symptom measures and identified six negative symptom self-
reported measures that assess amotivation. First, most recently, researchers have used the 
Motivation and Pleasure Scale-Self Report (MAP-SR; Llerena et al., 2013), which is the self-
report counterpart of the motivation and pleasure subscales of the Clinical Assessment Interview 
for Negative Symptoms (CAINS; Horan, Kring, Gur, Reise, & Blanchard, 2011; Kring, Gur, 
Blanchard, Horan, & Reise, 2013). The MAP-SR contains a subscale that assesses participants’ 
motivation and effort to engage in activities with other people, school or work activities, and 
hobbies or recreational activities over the past week. Notably, scores on the MAP-SR have 
shown large correlations with clinician-rated measures of negative symptoms (Engel & Lincoln, 
2016; Llerena et al., 2013), but the convergent validity with the individual amotivation subscales 
on negative symptom measures has not been assessed. Other negative symptom self-reported 
measures that assess amotivation include the Subjective Experience of Deficits in Schizophrenia 
(SEDS; Liddle & Barnes, 1988), which contains a subscale that assesses a person’s motivation 
and energy, and the Subjective Experience of Negative Symptoms (SENS; Selten, Sijben, Van 
den Bosch, Omloo-Visser, & Warmerdam, 1993) scale that assesses respondents’ subjective 
experience of the symptoms, including the avolition-apathy subscale, on the Scale for the 
Assessment of Negative Symptoms (SANS; Andreasen, 1984). However, the convergent validity 
of the motivation subscales of several of the older self-reported measures such as the SEDS and 
SENS has not been adequately explored with other measures of motivation (Lincoln et al., 2017).  
Clinician-rated motivation measures. Measures of motivation that are clinician-rated 
largely assess amotivation, apathy, or avolition—terms often used interchangeably in the 
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schizophrenia literature to describe negative symptom subscales related to reduced motivation 
(c.f., Foussias & Remington, 2010; Lincoln et al., 2017; Markou et al., 2013). As Lincoln et al. 
(2017) noted, almost all of the most widely used negative symptom measures contain subscales 
that assess reductions in motivation. For example, the SANS contains the avolition-apathy 
subscale that assesses participants’ energy, drive, and interest for work and/or school, daily self-
care, and non-passive activities, and the Brief Negative Symptom Scale (BNSS; Kirkpatrick et 
al., 2011; Strauss et al., 2012) contains an avolition subscale that assesses participants’ initiation 
and persistence for hobbies, self-care, treatment, and general activities.  
Aside from amotivation subscales from negative symptom measures, many schizophrenia 
researchers have also used two other clinician-rated measures to measure motivation. The first is 
the widely used three-item intrinsic motivation index from the clinician-rated Heinrichs-
Carpenter Quality of Life Scale (Heinrichs, Hanlon, & Carpenter, 1984), which was originally 
put forth by Nakagami, Xie, Hoe, and Brekke (2008). The index assesses participants’ sense of 
purpose, curiosity, and degree of motivation. The second measure, the clinician-rated version of 
the Apathy Evaluation Scale (AES-C; Marin, Biedrzycki, & Firinciogullari, 1991), has recently 
received increased attention in part due to the fact that it was developed specifically to measure 
apathy/amotivation. The original clinician-version of the AES (AES-C) contains 18-items and 
was introduced as a single factor measure that could be used for a range of clinical populations to 
assess motivational loss that was due to concurrent decreases in “the overt behavioral, cognitive, 
and emotional concomitants of goal-directed behavior” (Marin et al., 1991, p. 143). Faerden et 
al. (2008) conducted a factor analysis of the AES-C in a first-episode psychosis sample, finding 
that an abbreviated 12-item version of the AES-C provides a slightly more valid and reliable 
assessment of apathy in first-episode psychosis than the 18-item measure. Further, scores on both 
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the AES-C (12 and 18-item versions) and the QLS intrinsic motivation index have demonstrated 
adequate reliability as well as convergent validity with clinician-rated motivation or overall 
negative symptom scales (J. Choi et al., 2014; Faerden et al., 2008, 2009; Luther et al., 2015), 
but the convergent validity between these measures and self-reported and performance-based 
measures of motivation is not as established.   
Performance-based measures. Interest in creating more objective measures of 
motivation has led to the development and adaption of several performance-based paradigms to 
measure motivation (Fervaha, Duncan, et al., 2015; Green, et al., 2015), specifically extrinsic 
motivation, in schizophrenia. One difficulty in devising such assessments is that motivation is an 
important factor for completing most performance-based tasks (Markou et al., 2013). Further, 
performance-based tasks used to measure motivation often involve other processes such as 
reinforcement learning (i.e., modifying behavior in response to positive or negative feedback). 
To address these concerns, the Motivation Working Group of the Cognitive Neuroscience 
Treatment Research to Improve Cognition in Schizophrenia (CNTRICS; Carter et al., 2008) 
initiative identified and differentiated translational performance-based tasks that assess the most 
fundamental and unconfounded processes related to either motivation or reinforcement learning 
(Markou et al., 2013). This resulted in the identification of two types of motivation tasks, which 
both capture extrinsic motivation: Effort-based decision-making and outcome devaluation tasks. 
Notably, the selection of tasks was guided by the availability of evidence from human and 
animal research supporting the construct validity of each task. Accordingly, in order to reduce 
construct validity concerns (i.e., including measures that involve disparate processes unrelated to 
motivation), only measures that align with these two types of performance-based motivation 
measures were eligible for inclusion in the current meta-analyses. However, although some 
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studies have used outcome devaluation tasks with psychiatric populations (Gillan et al., 2011), 
these tasks are still primarily used in non-human studies and to our knowledge have not yet been 
used in people with schizophrenia; thus, only effort-based decision-making tasks were included 
in the current study. 
Effort-based decision-making tasks generally assess how much effort a person is willing 
to exert for a given level of reward. On these tasks, which have been described by Green et al., 
(2015) and Reddy, Horan & Green (2015), participants generally complete a computerized task 
that has forced choice-trials where participants are asked to choose between an option that 
requires low effort and provides low rewards or an option that requires relatively more effort and 
provides greater rewards. Several tasks assessing effort-based decision-making have been 
adapted from paradigms used to measure motivation with animals. Among these, the most 
widely used is the Effort Expenditure for Rewards Task (EEfRT; Treadway, Buckholtz, 
Schwartzman, Lambert, & Zald, 2009), which is a computerized effort-based decision-making 
task where participants choose between performing an easy task (pressing a computer key 30 
times in seven seconds with their index finger on their dominant hand) or a hard task (pressing a 
computer key 100 times in 21 seconds using their little finger of their non-dominant hand) for a 
specified amount of monetary reward on each trial; easy trials are worth $1.00, while the hard 
trials range in value from $1.24 to $4.30. Additionally, the probability of receiving the monetary 
award is also specified before each trial, with the probability of winning the specified award 
ranging from low (12%), medium (50%), and high (88%). After each trial, participants receive 
feedback about whether they won the reward.  
Other effort-based tasks used with people with schizophrenia have also been described by 
Green et al. (2015) and Reddy, Horan, & Green (2015) and generally involve forced choice-trials 
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where effort can be physical (i.e., squeezing a handgrip) or cognitive (i.e., identifying numbers 
on cards as odd or even) and increased effort is associated with greater rewards that are generally 
monetary. However, as others have noted (Green et al., 2015; Horan et al., 2015; Reddy, Horan, 
& Green 2015), many effort-based decision-making tasks have not received adequate 
psychometric evaluation in people with schizophrenia, and studies examining the relationship 
between effort-based decision-making tasks and clinician-rated motivation or negative symptom 
measures have yielded mixed results (c.f., McCarthy, Treadway, Bennett, & Blanchard, 2016; 
Treadway, Peterman, Zald, & Park, 2015). A meta-analytic approach may help to clarify these 
associations. Further, there is no agreed upon score derived from these measures that is used to 
assess motivation (Horan et al., 2015), which can complicate comparisons between studies 
(Reddy, Horan, & Green, 2015); therefore, to reduce the heterogeneity among scores for the 
current investigation, when appropriate, the most commonly used motivation score of percent of 
hard choices chosen across trials was used for the effort-based-decision-making tasks.  
Notably, effort-based decision-making tasks also differ from reinforcement learning tasks 
that are used in schizophrenia research. Reinforcement learning tasks generally ask a participant 
to repeatedly complete a task (i.e., pushing a button at a certain time or choosing one of two 
geometric shapes), which is followed by monetary (You won/lost $0.20) and/or verbal feedback 
(“Correct” or “Incorrect”) that is delivered probabilistically and varies in magnitude across the 
trials (Insel et al., 2014; Strauss et al., 2011). For these tasks, participants are instructed to 
incorporate feedback and adjust their behavior on the following trial in order to maximize verbal 
or monetary reward receipt. Thus, although motivation is involved in the completion of 
reinforcement learning tasks, these tasks differ in that they require participants to learn the 
appropriate response and then continuously update their responses based on feedback, making it 
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difficult to precisely identify if reduced task performance is due to difficulties in reinforcement 
learning or motivation. Thus, reinforcement learning tasks were not included in the current 
investigation.  
Current Study 
The overall aim of the current study was to conduct a series of meta-analyses that 
summarize the relationships between self-reported, clinician-rated, and performance-based 
measures of motivation across existing studies of people with schizophrenia-spectrum disorders. 
Given that SDT (Deci & Ryan, 1985a) has been a prominent organizing framework for 
motivation in schizophrenia research to date, the conceptualization proposed by Ryan and Deci 
(2000a) was utilized to identify and categorize motivation measures into intrinsic motivation, 
extrinsic motivation, or amotivation. Inclusion of measures that fall within these domains not 
only aligns with current thinking of motivation in schizophrenia but also will reduce the 
challenges in operationalizing motivation and help to alleviate construct validity concerns. 
Specifically, for self-reported and clinician-rated measures of intrinsic motivation and extrinsic 
motivation, we used a recent qualitative review by Kremen, Fiszdon, Kurtz, Silverstein, & Choi 
(2016) that describes extant intrinsic motivation and extrinsic motivation measures to guide 
measure inclusion. For self-reported and clinician-rated measures of amotivation, we included 
measures described as measuring amotivation in the review by Lincoln et al. (2017). These self-
reported and clinician-rated measures were chosen because they are among the most widely used 
and have been validated in people with schizophrenia, which can also help to reduce construct 
validity concerns. Lastly, the performance-based measures that were included, which all assess 
extrinsic motivation, were measures that aligned with Markou et al.’s (2013) review. 
The specific aims were to:  
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1) Identify the magnitude of the association between self-reported, clinician-rated, and 
performance-based measures of motivation. Consistent with some prior research (c.f., 
Evensen et al., 2009; Faerden et al., 2009; Strauss et al., 2016) and the notion that 
these measures are putatively assessing the same construct, we hypothesized that the 
magnitude of the relationship between these three motivation measurement types 
would be significant, positive, and represent a medium effect size.  
2) Identify the magnitude of the associations across measurement types within 
motivation domains (e.g., association between self-reported and clinician-rated 
intrinsic motivation). We hypothesized that there would be significant, medium, and 
positive relationships within the same motivation domain across the different 
assessment types.  
3) Examine moderators of the relationships between the different motivation 
measurement types, including age, gender, percent of the sample with a schizophrenia 
diagnosis, length of illness, and chlorpromazine equivalent doses. Given that shorter 
length of illness (Luther et al., 2015), and lower chlorpromazine equivalent doses 
(Kirsch, Ronshausen, Mier, & Gallhofer, 2007; Luther, Firmin, Minor, et al., 2016) 
have been linked to higher motivation, we hypothesized that the relationships 
between the motivation measurement types will be stronger with decreasing length of 
illness and chlorpromazine equivalent doses. All other moderator analyses were 
exploratory.  
Method 
Meta-Analytic Reporting Guidelines 
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 The evidence-based Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA; Moher, Liberati, Tetzlaff, & Altman, 2009) guidelines were used to ensure 
quality reporting of the meta-analytic findings.  
Literature Search  
 After consulting with a scientific librarian and referencing previously published meta-
analyses (O’Driscoll, Liang, & Mason, 2014; Pearlman & Najjar, 2014; Salyers et al., 2016) and 
guidelines (Card, 2012; Lipsey & Wilson, 2001), we conducted three steps to identify studies. 
First, searches were conducted in Embase, Medline, PsychINFO, PsychARTICLES, Pubmed, and 
Web of Science Core Collection, covering articles, theses/dissertations, and conference 
proceedings that were published up to September 7th, 2017. We included conference 
proceedings and theses/dissertations in order to reduce the possibility of publication bias and the 
file drawer problem (i.e., non-significant relationships not getting published in peer-reviewed 
articles) (Borenstein et al., 2009; Lipsey & Wilson 2001). Including conference abstracts was 
also based on the recommendations of several meta-analytic experts (Card, 2012; Lipsey & 
Wilson, 2001) and guidelines and standards for meta-analytic and systematic reviews from 
Cochrane (Higgins & Greene, 2011), the Agency for HealthCare Research and Quality (Balshem 
et al., 2013), and the Institute of Medicine (Eden, Levit, Berg, & Morton, 2011). Keywords for 
the search included all possible derivatives of the terms motivation and schizophrenia as well as 
an extensive combination of terms pertaining to measurement types (e.g., self-reported, clinician-
rated, performance-based). When available, English language and human filters were used. 
Second, reference sections of seven qualitative reviews related to the conceptualization or 
measurement of motivation in schizophrenia were reviewed (i.e., Green & Horan, 2015; Green et 
al., 2015; Kremen et al., 2016; Markou et al., 2013; Medalia & Brekke, 2010; Reddy, Horan, & 
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Green 2015; Strauss et al., 2014). Third, given that articles needed to contain two different types 
of motivation measures, we conducted forward searches of the original and/or psychometric 
validation articles for the included self-reported and performance-based motivation measures. 
See Figure 1 for PRISMA flow chart diagram. 
Study Selection: Inclusion and exclusion criteria 
Studies were eligible if they were 1) available in English, 2) included an empirical 
measure of at least two of the following: a self-reported, clinician-rated, or performance-based 
measure of motivation and, 3) included at least two motivation measures that mapped onto the 
domains of intrinsic motivation, extrinsic motivation, or amotivation. As described above, this 
process was grounded in extant literature and thus was guided by the measures described in the 
reviews by Kremen et al. (2016), Lincoln et al. (2017), and Markou et al. (2013). Specifically, 
we only included intrinsic motivation measures that aligned with those described by Kremen et 
al. (2016). Eligible amotivation measures were those that were described by Lincoln et al. 
(2017). For extrinsic motivation, all the performance-based motivation measures that aligned 
with those described by Markou et al. (2013) were eligible, as they assess a person’s willingness 
to exert effort for an external reward. In addition, self-reported measures of extrinsic motivation 
were also eligible to be included if they aligned with those described by Kremen et al. (2016). 
All potentially eligible measures that were considered for inclusion are reported in Appendix 
Table 1. Additional eligibility criteria included that studies 4) assessed motivation in a 
schizophrenia-spectrum sample and 5) reported a bivariate relationship between the included 
motivation measures. Only baseline relationships were examined in intervention or experimental 
studies. Studies were excluded if bivariate relationships were not available after contacting the 
authors or if a study sample overlapped with the sample from another study.  
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Coding  
 Eligible studies were coded according to a codebook that was developed based on 
guidelines from Card (2012) and Lipsey and Wilson (2001).  
 Sample-level information. Sample size and mean age, length of illness, chlorpromazine 
equivalent doses, as well as gender and diagnosis (e.g., percent schizophrenia), were coded for 
each study. Measurement type (i.e., self-reported) and motivation domain assessed were also 
coded.  
Effect size-level coding. For each study, the raw effect size (i.e., correlation coefficient) 
was extracted, representing the relationship between motivation measurement types. All effect 
sizes were converted into Pearson’s correlations. Further, for the measurement meta-analyses, if 
necessary, the effect size was reverse coded so that higher values on each motivation measure 
represented greater motivation. For the domain meta-analyses, if necessary, the effect sizes were 
reverse coded so that all domain measures were scored in the same direction (i.e., higher scores = 
greater amotivation, greater intrinsic motivation, and greater extrinsic motivation). If a study 
included multiple effect sizes that captured the same type of relationship (i.e., relationship 
between self-reported and clinician-rated motivation measures) or domains (i.e., self-reported 
and clinician-rated intrinsic motivation), the effect sizes assessing the same type of relationship 
or domain were averaged and weighted by sample size in order to reduce bias and not violate the 
assumption of independence (Card, 2012). For both the measurement and the domain meta-
analyses, if a measure assessed multiple symptom or motivation domains, we included only 
relationships with the subscale or items that aligned with motivation or the respective domain of 
interest when coding and ultimately analyzing the effect sizes. If a study did not report the 
relevant correlation or measure information, study authors were emailed. All data were originally 
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coded into Excel and then imported into the Statistical Package for the Social Sciences (SPSS), 
version 22.0 and Comprehensive Meta-Analysis, Version 3 (CMA; Borenstein et al., 2014).   
Analyses 
Descriptive statistics were conducted using SPSS. Mean overall effect sizes were then 
computed in CMA using a random-effects model, which accounts for both within-study and 
between-study variability (Lipsey & Wilson, 2001). We first aimed to conduct three separate 
meta-analyses to investigate the relationships between 1) self-reported and clinician-rated, 2) 
performance-based and clinician-rated, and 3) self-reported and performance-based motivation 
measures. Based on extant motivation measures described in Kremen et al. (2016), Lincoln et al. 
(2017), and Markou et al. (2013), we also aimed to calculate three additional meta-analyses 
examining the relationships within motivation domains across the different assessment types: 1) 
self-reported and clinician-rated intrinsic motivation, 2) self-reported and clinician-rated 
amotivation, and 3) self-reported and performance-based extrinsic motivation measures. For all 
meta-analyses, the magnitude of the overall effect sizes was interpreted based on Cohen’s (1992) 
recommendation for correlations where .10 is small, .30 is medium, and .50 is large.  
For each meta-analysis, a one-study removed sensitivity analysis was conducted in CMA 
to determine if one study was unduly impacting the overall effect size. This analysis is conducted 
by running each meta-analysis repeatedly, with a different study removed each time (Borenstein, 
Hedges, Higgins, & Rothstein, 2009). CMA produces a forest plot and effect size point estimates 
that visually and numerically depict how the overall mean effect size would be affected if each 
study were removed one at a time (Borenstein et al., 2009). Studies were considered for removal 
if they visually appeared to be outliers and the overall effect size substantially changed after 
removing the study.  
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The presence of heterogeneity among the included effect sizes of each meta-analysis was 
identified using the Q-statistic (Card, 2012). To assess the extent of any identified heterogeneity, 
the I2 index was examined (Higgins & Thompson, 2002; Huedo-Medina, Sánchez-Meca, Marín-
Martínez, & Botella, 2006) to determine the percentage of variation that is due to between-study 
variability; values greater than or equal to 25% suggest greater between-study variability than 
would be expected by chance (Huedo-Medina et al., 2006). More specifically, I2 index values of 
25%, 50% and 75% are considered low, medium, and high amounts of variability, respectively 
(Higgins & Thompson, 2002; Huedo-Medina et al., 2006). Moderation analyses for each meta-
analysis were conducted when the Q-statistic was significant and the I2 index was 25% or 
greater.  
All proposed moderators were continuous and were assessed in CMA with meta-
regressions using a random effects model. At least six studies needed to provide data in order for 
each moderation analysis to be conducted (Fu et al., 2011). Because meta-regressions use 
listwise deletion, each moderator was examined individually to maximize the number of studies 
included. Moderators were considered significant if the associated beta weight was significant (p 
< .05) and the I2 index decreased when compared to the I2 index of the main corresponding meta-
analysis.  
Finally, publication bias was also examined using two steps. First, funnel plots were used 
to see if they were roughly triangular in shape or had an asymmetrical distribution around the 
mean effect size (Borenstein et al., 2009; Card, 2012), which would indicate potential bias. 
Second, Egger’s regression test (Egger, Smith, Schneider, & Minder, 1997), which regresses the 
normalized effect estimates (i.e., effect size divided by its standard error) against studies’ 
precision (Egger et al., 1997), was conducted for each meta-analysis; Egger’s test suggests that 
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publication bias is present when the intercept is significant (p < .05). Some authors suggest that a 
minimum of 10 studies is needed in order to be adequately powered to detect publication bias 
(Kepes, Banks, McDaniel, & Whetzel, 2012). 
Results 
Study Characteristics  
Forty-five unique studies were eligible to be included in the meta-analyses (see Figure 1 
for Study Retrieval Flow Diagram). Of these, 33 examined the relationship between self-reported 
and clinician-rated motivation measures, 12 examined the relationship between performance-
based and clinician-rated motivation, and two studies assessed the relationship between self-
reported and performance-based motivation measures (one study assessed all three 
relationships). Summary study characteristics appear in Table 1, and individual study 
characteristics, motivation measures, and effect sizes are presented in Appendix Table 2. Across 
all eligible studies, 2,781 participants with a schizophrenia-spectrum diagnosis were included, 
representing 13 countries. The most commonly used self-reported measure was a version of the 
Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR; J. Choi et al., 2010), while 
the most commonly used clinician-rated motivation measure was the amotivation subscale 
(Fervaha, Foussias, Agid, & Remington, 2014; Liemburg et al., 2013) of the Positive and 
Negative Syndrome Scale (PANSS; Kay et al., 1987). Finally, the majority of studies measuring 
performance-based motivation used the Effort Expenditure for Rewards Task (Treadway, 
Buckholtz, Schwartzman, Lambert, & Zald, 2009). Forty-two studies had been published in a 
peer-reviewed journal article, while three studies were conference abstracts.  
For the domain meta-analyses, four studies assessed the relationship between self-
reported and clinician-rated intrinsic motivation, and 23 assessed the relationship between self-
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reported and clinician-rated amotivation. No studies assessed the relationship between self-
reported and performance-based extrinsic motivation. See Table 2 and Appendix Table 2 for 
more information.  
Of note, several of the proposed meta-analyses had few studies (i.e., 2 or 4). However, 
based on Borenstein et al.’s (2009) recommendation to conduct and report meta-analyses even 
when the number of studies is small and in light of our goal to comprehensively review the 
overlap between different motivation measurement types in extant studies, we still conducted 
meta-analyses with few studies even though they were likely underpowered to detect effects.   
Sensitivity Analyses  
 Visually examining the one-study removed forest plots (available from the first-author 
upon request) for each of the five meta-analyses (three measurement type and two domain) 
suggested that there was some variation among the study-level effect sizes. In particular, the 
meta-analysis examining the relationship between performance-based and clinician-rated 
motivation appeared to contain a potential outlier. Examination of the effect size point estimates 
suggested that McCarthy, Treadway, Bennett, & Blanchard (2016) may be overly influencing the 
mean effect size; compared to most of the other included studies, this study also had several 
demographic differences (e.g., older sample). Given the effect size impact and demographic 
differences of McCarthy et al. (2016), it was removed from all further analyses. No additional 
studies were removed from the remaining meta-analyses.  
Main Analyses 
 For the meta-analyses examining the overall associations between different motivation 
measurement types, two of the three meta-analyses produced significant effect sizes, which were 
positive and small to medium in magnitude; only the meta-analysis between self-reported and 
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performance-based motivation measures was non-significant, evidencing a negligible overall 
effect size. Of the two conducted meta-analyses examining the relationships within motivation 
domains across different measurement types, only the meta-analysis examining the association 
between self-reported and clinician-rated amotivation was significant, demonstrating a medium 
effect size. A summary of the meta-analytic statistics is presented in Table 2.  
Self-reported––clinician-rated meta-analysis. Thirty-three studies (including the three 
conference abstracts) had effect size data for the meta-analysis examining the relationship 
between self-reported and clinician-rated motivation measures (see Table 2, Figure 2). Generally 
consistent with our hypothesis, there was a positive, significant overall effect size between these 
motivation measures that was approaching a medium effect size (r = .27, p <.001), suggesting 
that higher levels of self-reported motivation were associated with higher levels of clinician-rated 
motivation. Notably, this correlation suggests that the shared variance between these motivation 
measurement types was approximately 7.29%. Further, sample-level correlations ranged from r = 
-.11 to r = .75. To ensure that DeRosse, Nitzburg, Kompancaril, and Malhotra (2014) was not 
unduly influencing the effect size given that this study made up 21.4% of the overall sample, we 
also calculated the effect size without this study; this revealed a similar effect size (r = .28, p 
<.001). Similarly, we also assessed the impact of the conference abstracts on the overall effect 
size; when the three conference abstracts were excluded, the effect size was again similar (r = 
.28, p <.001), suggesting that the conference abstracts were also not unduly influencing the effect 
size. Thus, both DeRosse et al. (2014) and the conference abstracts were retained in all additional 
analyses. In terms of heterogeneity, the Q-statistic for the overall effect size with all 33 studies 
was significant (p <.001), with the I2 index (72.70%) suggesting there was a medium to high 
amount of heterogeneity and that moderator analyses would be appropriate (see below).  
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Performance-based––clinician-rated meta-analysis. After removing McCarthy et al. 
(2016), there were 11 studies that provided data for the relationship between performance-based 
and clinician-rated motivation measures (Table 2, Figure 3). Analyses indicated that there was a 
positive, small, significant overall effect size (r = .21; p < .001) between these two measurement 
types, suggesting that higher levels of performance-based motivation were associated with higher 
levels of clinician-rated motivation. Of note, this finding is in the hypothesized direction, but the 
magnitude of the effect size was slightly lower than hypothesized. Further, this correlation 
suggests that the shared variance between these motivation measurement types was 
approximately 4.41%. All of the included samples found positive relationships between the 
measurement types (ranging from r = .05 to r = .52). Significant heterogeneity was not present 
among the effect sizes (Q-statistic, p = .32; I2 = 13.09%).   
Self-reported––Performance-based motivation association. Two studies provided data 
on the relationship between self-reported and performance-based motivation (Table 2, Figure 4). 
Contrary to hypothesis, the overall effect size was negligible and non-significant (r = -.001, p = 
.992). One of the studies found a negative relationship (r = -.07), while the other study found a 
positive relationship between these measurement types (r = .17). There was not significant 
heterogeneity in the included effect sizes (Q-statistic, p = .26; I2 = 20.71%). However, given that 
these analyses were based on only two studies, the results should be interpreted cautiously.  
Motivation domain associations. Two of the within domain meta-analyses were able to 
be conducted (see Table 2). Consistent with our hypothesis, the overall effect size for the meta-
analysis between self-reported and clinician-rated amotivation was significant, positive, and 
medium in magnitude (r = .34, p <.001); this was based on 23 studies. The effect size for the 
meta-analysis examining the relationship between self-reported and clinician-rated intrinsic 
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motivation was small and positive but non-significant (r = .16, p = .259); however, because only 
four studies were included, this meta-analysis was likely underpowered. See Figures 5 and 6 for 
forest plots. Heterogeneity analyses indicated that significant heterogeneity was present to a 
medium to large extent among the associations between both self-reported and clinician-rated 
amotivation (Q-statistic, p < .001; I2 = 77.34%) and intrinsic motivation measures (Q-statistic, p 
= .008; I2 = 74.67%).  
Moderator Analyses 
Meta-regression analyses. Given that significant heterogeneity was present to a medium 
or large extent for three of the meta-analyses, we aimed to conduct moderator analyses in 
attempts to identify the source of the heterogeneity in these meta-analyses. However, the meta-
analysis of self-reported and clinician-rated intrinsic motivation had only four studies (i.e., did 
not meet the threshold of six; Fu et al., 2011), making it ineligible for moderator analyses. We 
examined five potential continuous moderators, including mean age, length of illness, 
chlorpromazine equivalent doses, as well as % female and % schizophrenia in the meta-analyses 
between self-reported and clinician-rated motivation measures and then self-reported and 
clinician-rated amotivation measures. Results are presented in Table 3. Consistent with our 
hypothesis, length of illness significantly moderated the relationship between self-reported and 
clinician-rated motivation (b = -.014, p = .04, I2 = 59.26) so that for every one year increase in 
length of illness, the relationship between self-reported and clinician-rated motivation weakened 
by .014. Contrary to our hypothesis, mean chlorpromazine equivalent doses were not significant 
moderators of either relationship. No additional moderators were significant, and there were no 
significant moderators of the relationship between self-reported and clinician-rated amotivation. 
Publication Bias 
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Analyses examining publication bias were conducted for all meta-analyses with more 
than two studies (i.e., a minimum of three studies is required to conduct the analyses) to ensure 
that bias was not influencing both significant and non-significant overall mean effect sizes. 
Funnel plots (available from the first-author upon request) of the effect sizes for the four eligible 
meta-analyses were relatively symmetrical and triangular, suggesting that publication bias was 
not present. Egger’s regression test of the intercept was also not significant (all p’s > .05) for any 
of the four meta-analyses, further supporting the notion that publication bias was not present. 
However, given that several of the meta-analyses had fewer than or close to 10 studies, it is 
possible that we were underpowered to detect publication bias in these meta-analyses.  
Discussion 
In an effort to inform the conceptualization, measurement, and treatment of motivation in 
schizophrenia, we conducted several meta-analyses to identify the overlap or discrepancy 
between extant motivation measures. Forty-five unique studies were identified, and mean 
weighted overall effect sizes were calculated between clinician-rated and both self-reported and 
performance-based motivation measures and between self-reported and performance-based 
motivation measures. Partially consistent with our hypotheses, our results suggest that there are 
significant and positive relationships between clinician-rated and both self-reported and 
performance-based motivation measures that represent small to medium overall effect sizes. 
Further, these results appeared not to be unduly influenced by outliers or publication bias. We 
also found a negligible, non-significant overall effect size between self-reported and 
performance-based motivation measures, which was contrary to our hypothesis. However, given 
that only two studies were included in the self-reported and performance-based motivation 
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measures meta-analysis, these results should be interpreted cautiously, as we were likely 
underpowered to detect effects.  
The overall effect size between self-reported and clinician-rated motivation measures was 
also relatively larger than the overall effect sizes between performance-based motivation and 
both clinician-rated and self-reported motivation measures. This may in part be explained by the 
greater degree of similarity between self-reported and clinician-rated assessment methods. First, 
the self-reported and clinician-rated motivation measures often have similar item content. For 
example, both the MAP-SR and SANS contain items assessing motivation for work and/or 
school. Second, both self-reported and clinician-rated motivation measures also have a shared 
data source: the participants’ self-reported information. Although clinician-rated measures may 
be more objective measures of motivation as they incorporate divergent sources of information 
(e.g., medical chart or informant information) and clinician judgment (e.g., determining the 
validity of the participant’s self-reported information), the shared data source could also help to 
explain the stronger observed correlation.  
In contrast, the performance-based measures do not share method variance and have less 
content overlap with both the clinician-rated and self-reported motivation measures; their 
relationships were likely smaller due to several important factors. First, performance-based 
measures assess one’s behavioral performance on a time-limited task (in a lab setting). On the 
other hand, clinician-rated measures utilize a combination of self-reported, clinician assessed, 
and informant reported perceptions of behavior for a longer time period (i.e., week to a month) 
out in the community, while self-reported measures focus solely on a person’s perceptions of 
their behavior generally over the past week or month. Further, although all broadly assess one’s 
willingness to expend effort or to complete a task (i.e., pushing a button vs. going to work or 
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school), the time frame of reward receipt and the type of tasks/level of effort involved differ. For 
example, within the performance-based measures, participants are reinforced almost 
instantaneously and frequently during the task, whereas clinician-rated and self-reported 
measures largely assess domains that involve delayed rewards (e.g., a paycheck or an educational 
degree). This is particularly important given that people with schizophrenia have difficulties 
representing, maintaining, and updating the value of future rewards (Strauss et al., 2014), 
especially as the length of time of reward receipt increases (Heerey, Robinson, McMahon, & 
Gold, 2007); thus, we might expect divergent behavioral responses (i.e., greater or reduced effort 
or task engagement) to tasks that offer frequent rewards versus tasks that offer less frequent 
rewards. Similarly, considerably more effort is required to work or attend school compared to 
pushing a button or gripping a lever. Thus, the divergent timeframe, rewards, and tasks assessed 
likely contribute to the smaller observed effect sizes between performance-based and both 
clinician-rated and self-reported motivation measures.  
Of note, our findings also point to the need for additional work aimed at clarifying the 
overlap or disparity between self-reported and performance-based motivation measures. Only 
two studies were eligible to be included in the meta-analysis examining this relationship, and the 
effects in these studies were in opposite directions. Considering that prior studies have 
questioned the validity and reliability of self-reported measures for people with schizophrenia 
(Gupta, Holshausen, Gou, & Bowie, 2014; Takeuchi, Fervaha, & Remington, 2016) and several 
researchers have pointed to the need for additional psychometric evaluation studies of 
performance-based motivation measures (Barch, Gold, & Kring, 2017; Reddy et al., 2015), 
future studies are needed to more conclusively validate these measures in schizophrenia samples 
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and understand the level of overlap in the underlying construct(s) that both self-reported and 
performance-based motivation measures are assessing.  
Despite these differences in methods of measurement, the magnitude of the effect sizes 
still suggests some evidence of convergent validity, particularly between clinician-rated and both 
self-reported and performance-based motivation measurement methods. However, compared to 
the effect size between self-reported and clinician-rated motivation measures, there was 
relatively less convergent validity between the performance-based and clinician-rated motivation 
measures. Importantly, although there is some evidence of convergent validity between clinician-
rated and both self-reported and performance-based motivation measures, the magnitude of the 
overall effect sizes also suggests that these measurement types are assessing small amounts of 
shared variance. Indeed, the overall effect size between self-reported and clinician-rated 
motivation measures indicated that the measures were assessing only 7.29% of similar 
underlying variance, while the performance-based and clinician-rated measures were sharing 
only 4.41% of similar variance. These findings indicate that although clinician-rated and both 
self-reported and performance based-measures are assessing some shared underlying construct, 
there is more variability than similarity in the underlying construct that is being assessed by the 
different motivation measurement types.  
 When possible, we also conducted moderator analyses among the meta-analyses with 
significant heterogeneity, namely the overall self-reported and clinician-rated meta-analysis as 
well as the self-reported and clinician-rated intrinsic motivation and amotivation domain meta-
analyses. The remaining two meta-analyses did not have significant heterogeneity, suggesting 
there was more similarity among the included study effect sizes. Consistent with our hypothesis, 
length of illness was a significant moderator of the overall relationship between self-reported and 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
clinician-rated motivation measures, so that as length of illness increased, the relationship 
between the motivation measures weakened. Although the exact mechanism causing this reduced 
relationship as the length of illness progresses is not evident from the current findings, there are 
several factors that could be explored in future research. First, as the length of illness increases 
and motivation deficits become more prolonged, some areas or domains of motivation might be 
differentially impacted over time (Luther et al., 2015), which may lead to a reduced association 
between motivation measures that assess different domains. Further, it may be that over time, a 
person’s perception of their motivation becomes less aligned with behavior. For example, a 
mismatch between perception and behavior might result from prolonged experience with factors 
such as stigma (Firmin, Luther, Lysaker, Minor, & Salyers, 2016), defeatist performance beliefs 
(Grant & Beck, 2009), less stimulating environments (e.g., a hospital), and unfulfilled basic 
psychological needs (Ryan & Deci, 2000b). Future research is needed to clarify factors or 
additional moderators that might impact the relationship between self-reported and clinician-
rated motivation measures, especially as the length of illness increases. 
In part to identify whether individual motivation domains would also help to explain the 
observed heterogeneity, we explored the relationships across assessment types within domains 
for intrinsic and amotivation domains. No studies assessed the relationship between different 
extrinsic motivation measures types, so this relationship was unable to be analyzed. Contrary to 
our hypothesis, the overall relationship between self-reported and clinician-rated intrinsic 
motivation was small and non-significant. However, few studies were included, and the self-
reported intrinsic motivation measures largely assessed intrinsic motivation for a specific task, 
while the clinician-rated measure assessed intrinsic motivation for tasks more generally. As J. 
Choi et al. (2014) suggested, the limited relationship may in part be due to the fact that 
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motivation for different tasks was assessed, but additional research is needed to clarify this 
relationship. Further, in line with our hypothesis, the overall mean effect size between self-
reported and clinician-rated amotivation measures was positive, significant, and represented a 
medium effect size. Notably, this overall effect size was relatively larger than the overall effect 
size between all included self-reported and clinician-rated motivation measures, suggesting that 
amotivation measures across measurement types may be more strongly related than measures 
assessing different motivation domains (i.e., relationship between self-reported intrinsic 
motivation and clinician-rated amotivation). Indeed, this is consistent with SDT, which describes 
these motivation domains as distinct yet possibly co-occurring constructs (Ryan & Deci, 2000a). 
For instance, it is possible that someone is motivated to do something both because of the 
pleasure one derives from the activity as well as the monetary reward associated with it (e.g., 
writing and publishing books). At other times, people may be extrinsically motivated but not 
intrinsically motivated to complete a specific task. Therefore, we may not always expect these 
different types of motivation to strongly correlate with one another. However, given that we were 
unable to conduct one of the domain analyses and few studies were included in the intrinsic 
motivation domain meta-analyses, additional work clarifying the overlap both within and 
between different motivation domains is needed. Further, our results may be impacted by how 
we categorized measures into different motivation domains. Indeed, Deci and Ryan’s (2008) 
more recent macrotheory of motivation differentiates motivation domains into autonomous 
motivation, controlled motivation, and amotivation. Notably, this newer theory describes 
autonomous and controlled motivation as involving both internal and external processes. Thus, 
future research may benefit from exploring the association of these more recent motivation 
domains as well as clarifying which measures assess these constructs. Similarly, although Deci 
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and Ryan’s (1985a) seminal work on differentiating motivation into the domains of intrinsic 
motivation, extrinsic motivation, and amotivation has served as a critical guide for schizophrenia 
motivation research, future work focused on the conceptualization and measurement of 
motivation in schizophrenia may benefit from incorporating Deci and Ryan’s (2008) more recent 
theory.  
It is also useful to frame these results in the context of different psychometric theories 
and methods. Specifically, examining the overlap between different methods of assessing 
motivation is consistent with the Multitrait-Multimethod Matrix (MTMM; Campbell & Fiske, 
1959), which is a statistical approach that aims to examine the suitability of tests to measure a 
specified construct (i.e., construct validity). Briefly, Campbell and Fiske (1959) described that in 
order for tests to have adequate construct validity, they must demonstrate adequate convergent 
and discriminant validity with different measurement methods of the same construct (i.e., self-
reported, clinician-rated motivation measures) and distinct traits that are not theoretically related 
(i.e., positive symptoms), respectively. Further, they, along with others (Pitoniak, Sireci, & 
Luecht, 2002), argued that in order for adequate convergent validity to be established, 
correlations among the different measurement methods of a construct should be significantly 
different from zero and be “sufficiently large to encourage further examination of validity” 
(Campbell & Fiske, 1959, p. 83). Although additional research on the discriminant validity of the 
included motivation measures is needed to adequately use the MTMM, given that the largest 
overall effect size observed between performance-based and other methods of motivation 
assessment was only small in magnitude, it is uncertain if performance-based motivation 
measures meet MMTM’s criteria for adequate convergent and thus construct validity. However, 
some have noted (Cohen, 2016) that standard psychometric methods may fail to accurately 
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evaluate the complex associations with more novel objective approaches such as performance-
based measures of motivation. Instead, researchers suggest that methods such as argument-based 
validity (see Kane, 1992 for more information on this approach) might be a better means to 
assess the validity of these measures. Despite these different approaches to examining the 
validity of measures, it is clear that additional research examining the construct validity of 
performance-based as well as self-reported and clinician-rated motivation measures is needed in 
order to bolster our assumptions that these measures are truly assessing motivation.  
In addition to other limitations common to all meta-analyses (e.g., limited by the 
constraints of the primary studies; Borenstein et al., 2009), there are also several study-specific 
limitations that should be considered when interpreting the findings from this study. First, we 
included only studies that were available in English. Second, despite a large number of studies 
identified during the initial literature search, few were able to be included in the current study (in 
part due to the recency of some assessment methods), which limited our ability to conduct all 
proposed meta-analyses and moderator analyses. However, many of the included study-level 
correlations were not previously published and were obtained through contacting researchers, 
which reduces the possibility of publication bias. In addition, although we used SDT and recent 
literature reviews on motivation and negative symptom measures to guide our inclusion of 
measures, we did not include all possible measures of “motivation.” This was partially in attempt 
to reduce construct validity concerns and to address one of the common criticisms of meta-
analyses: comparing apples to oranges (Borenstein et al., 2009), or in this case, comparing 
motivation measures that might be assessing constructs that are too disparate from one another. 
However, because our goal was to draw conclusions about the way the literature is currently 
assessing a particular “fruit” (i.e., motivation), we still aimed to include a range of measures that 
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have been used to measure motivation in the schizophrenia literature by basing our measure 
inclusion on multiple reviews that describe a large array of the most widely-used motivation and 
negative symptom measures. In addition, as previously discussed, many scores can be derived 
from performance-based measures, and there is no completely agreed upon score that is used to 
assess “motivation.” To reduce issues surrounding interpretation of different scoring methods 
(Reddy, Horan, & Green, 2015), when appropriate, this study used the most commonly used 
motivation score of percent of hard choices chosen across trials. However, future work is needed 
to identify if other scoring methods (e.g. creating a difference score across different conditions; 
Horan et al., 2015) might be more precise measures of “motivation” or at least more in line with 
self-reported and clinician-rated motivation.  
Despite these limitations, our findings point to several areas of research related to the 
assessment of motivation in schizophrenia. Most importantly, additional work examining the 
construct validity (i.e., convergent and discriminant validity), particularly of performance-based 
motivation measures, is needed. Ideally, during these validation efforts, researchers will also 
utilize more rigorous methods, such as the MTMM or argument-based validity, to examine the 
construct validity of these motivation scales. Second, future research clarifying the construct or 
convergent validity of motivation scales may also benefit by further investigating their 
relationship with overall negative symptoms scores. This is particularly relevant given that 
several of the first-generation negative symptoms measures such as the SANS or the PANSS 
have been criticized for not adequately assessing internal experiences or the full range of each 
negative symptom domain (Blanchard et al., 2010), while the second-generation negative 
symptom measures such as the CAINS and the BNSS have been developed in part to address 
these limitations of the first-generation negative symptom assessments. Similarly, as noted 
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above, researchers have identified that there are two key subdomains of negative symptoms 
(Green et al., 2012; Strauss et el., 2013), with amotivation or the experiential negative symptoms 
being one of the domains. However, depending on the scale or factor analyses (Blanchard & 
Cohen, 2005; Foussias & Remington, 2010; Liemburg et al., 2013), anhedonia is at times 
included in the experiential negative symptom subscale. Although amotivation and anhedonia are 
thought of as distinct (yet partly overlapping) negative symptoms (Foussias & Remington, 2010), 
future research could also benefit from clarifying the overlap between these symptoms as well as 
examining whether there is greater concordance between measurement types when looking at 
both amotivation and anhedonia. An additional important area of future research involves 
identifying what are the “best” or “gold-standard” measures of motivation across each 
measurement type, or similarly, what measures or combinations of measures most closely 
resemble the different motivation domains and the multidimensional construct of “motivation.” 
Finally, as others have suggested (J. Choi et al., 2014; Fervaha, Foussias, et al., 2015), another 
important area of future research is to examine what type of motivation measurement (as well as 
motivation domains) may be most predictive of functioning and other symptoms. 
The findings from these meta-analyses can also be used to guide and improve our 
assessment of motivation in schizophrenia. These findings suggest that these three motivation 
measurement types are at best only assessing a small amount of a shared underlying construct. 
Therefore, in contrast to some current practices, these three motivation measurement types 
should not be used interchangeably to assess “motivation.” Instead, at the outset, researchers and 
clinicians should refer to each measure as the specific construct or domain it was designed to 
measure or capture. Indeed, recent work on motivation in schizophrenia (J. Choi et al., 2014; K.-
H. Choi, Saperstein, & Medalia, 2012; Luther et al., 2015) has begun to use more precise 
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language when describing motivation measures. Although more work clarifying the construct 
validity of these scales is needed, future researchers may also follow this trend and describe the 
included clinician-rated scales as scales assessing more trait levels of general intrinsic motivation 
(or amotivation) or describe performance-based measures as measures assessing state levels of 
extrinsic motivation for monetary rewards or state levels of effort-based decision-making for 
monetary rewards. Similarly, self-reported measures of motivation should be accurately 
described. For example, these measures could be described as assessing state motivation for a 
specific task or as assessing trait-like motivation for a range of activities or tasks instead of 
measures of “motivation.” Taken together, our findings highlight the limited overlap between 
motivation measures and suggest that additional research involving the assessment of motivation 
is needed to help improve our understanding and treatment of motivation in people with 
schizophrenia. 
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Figure 1. PRISMA Study Retrieval Flow Diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Includes conference abstracts 
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Additional records identified through other 
sources (forward searching, author suggestions, 
database email alerts, review article references) 
(n = 2465) 
Records excluded (n = 3276) 
 After screening title: 2432 
 After screening title and abstract:  
844 
Full-text articlesa excluded, with 
reasons 
(n = 929) 
 Conceptual/review article: 13 
 Not with people with schizophrenia-
spectrum disorders: 25 
 Did not assess motivation with ≥ two 
eligible motivation measures: 857 
 Unable to acquire needed data after 
contacting the authors: 34 
 
 
Records eligible for 
meta-analysis 
(n = 74) 
Records eligible for 
meta-analysis, with 
overlapping samples 
removed 
(n = 45)  
Records screened  
(n = 4279)  
  
Records identified through 
original search in electronic 
databases  
(n = 4199) 
Records after duplicates removed 
(n = 4279) 
Full-text articlesa 
assessed for eligibility 
(n = 1003) 
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Figure 2. Forest plot of the meta-analysis examining the relationship between self-reported and 
clinician-rated motivation measures (k = 33)  
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Figure 3. Forest plot of the meta-analysis examining the relationship between performance-
based and clinician-rated motivation measures (k = 11) 
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Figure 4. Forest plot of the meta-analysis examining the relationship between self-reported and 
performance-based motivation measures (k = 2) 
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Figure 5. Forest plot of the meta-analysis examining the relationship between self-reported and 
clinician-rated amotivation measures (k = 23) 
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Figure 6. Forest plot of the meta-analysis examining the relationship between self-reported and 
clinician-rated intrinsic motivation measures (k = 4)  
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Table 1 Overall characteristics across included samples (k = 45)  
Sample Characteristics Mean (SD) K 
Age  38.0 (6.6) 45 
Percent Female 37.6 (9.7) 45 
Percent Diagnosisa 
 
38 
Schizophrenia 83.8 (16.8) - 
Schizoaffective 12.9 (13.9) - 
Other Psychosis 3.1 (9.2) - 
Length of illness 13.7 (7.0) 21 
Chlorpromazine equivalent doses  482.4 (212.2) 21 
Study Characteristics Mean (SD) K 
Data source (k, %) 
 
45 
Published Articleb 42 (93.3) - 
Conference Abstract  3 (6.7) - 
Median Year (range) 2015 (1998-2017) 45 
Mean Sample size (range) 61.8 (11-486) 45 
Study Location (k, %) 
 
45 
Asia  10 (22.2) - 
Europe   11 (24.4) - 
North America 24 (53.3) - 
a 
All included samples had schizophrenia-spectrum disorder diagnoses.  
b 
Includes studies that were published as both a conference abstract and article. 
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Table 2  Summary of Mean Effect Sizes for the Associations Between Motivation Measures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. k  = number of eligible studies included in the effect size calculation, if applicable; n = total sample combined across eligible studies; ES = weighted and  
averaged correlation coefficient across eligible studies; 95% CI = 95% confidence interval for the mean effect size; Z = z-test value for statistical significance  
of the mean effect size; Q = test for presence of heterogeneity; I
2
 = indicates the extent of between-study variability; IM = intrinsic motivation; EM = extrinsic  
motivation; AM = amotivation. 
a 
This relationship is listed because based on extant motivation measures, this relationship could be examined; however, no available studies have examined  
this relationship.  
*p< .05 
**p< .01 
***p< .001
Association k n ES - r 95% CI z Q I2 
Self-reported—Clinician-rated 33 2270 .27 [.19, .35] 6.26*** 117.23*** 72.70 
Performance-based—Clinician-rated 11 445 .21 [.10, .32] 3.77*** 11.51 13.09 
Self-reported—Performance-based 2 128 -.001 [-.21, .21]  -.01 1.26 20.71 
IM Self-reported—IM Clinician-rated 4 209 .16 [-.12, .42] 1.13 11.84** 74.67 
EM Self-reported—EM Performance-
baseda 
0 - - - - - - 
AM Self-reported—AM Clinician-
rated 
23 1847 .34 [.24, .43] 6.52*** 97.08*** 77.34 
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Table 3 Moderator Analyses 
Association  Moderator  k B SE 95% CI z I2 
 
 
Self-Reported—
Clinician-rated  
Mean age 33 -
.006 
.006 [-.018, 
.006] 
-.98 68.70 
Mean illness length 17 -
.014 
.007 [-.029, 
.000]a 
-
2.01* 
59.26 
Mean CPZ equivalent 
doses 
13 .000 .000 [.000, .001] .19 50.16 
% female 33 .007 .004 [-.002, 
.016] 
1.56 66.86 
% schizophrenia diagnosis 27 -
.001 
.003 [-.006, 
.004] 
-.27 57.23 
 
 
AM Self-
Reported—AM 
Clinician-rated 
Mean age 23 .005 .009 [-.013, 
.022] 
.50 76.50 
Mean illness length 10 -
.008 
.016 [-.038, 
.023] 
-.50 66.74 
Mean CPZ equivalent 
doses 
7 .000 .000 [-.001, 
.000] 
-.90 63.06 
% female 23 .007 .005 [-.003, 
.017] 
1.41 70.72 
% schizophrenia diagnosis 17 .000 .003 [-.005, 
.006] 
.15 52.05 
Note. k = number of studies reporting the moderator and included in the meta-regression; B = regression coefficient; 
SE = standard error;  
95% CI = 95% confidence interval for regression coefficient; z = z-test value for statistical significance of 
regression coefficient; I
2
 = indicates  
the extent of between-study variability that is unexplained after accounting for the moderator; CPZ = 
chlorpromazine equivalent doses;  
AM = Amotivation.  
a 
Full CI: [-.0286, -.0003] 
*p< .05 
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Highlights  
 An array of motivation measures has been used in schizophrenia research.  
 However, the convergent validity of these assessment methods is mixed.  
 These meta-analyses summarized the relationships between motivation measure types.  
 Results suggest negligent to medium relationships between motivation measure types.  
 These measures are assessing a small amount of a shared underlying construct.  
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